Jefferies Group Gives Buy (N/A) Rating to Aveo Pharmaceuticals (AVEO)

By admin | 6 years ago

Aveo Pharmaceuticals (NASDAQ: AVEO)‘s stock had its “buy (n/a)” rating restated by equities researchers at Jefferies Group (NYSE: JEF) in a report issued on Monday.

Shares of Aveo Pharmaceuticals opened at 12.88 on Monday. Aveo Pharmaceuticals has a one year low of $10.40 and a one year high of $21.55. The company’s market cap is $561.2 million.

Aveo Pharmaceuticals last issued its quarterly earnings data on Thursday, May 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.01. The company’s revenue for the quarter was down 99.4% on a year-over-year basis. On average, analysts predict that Aveo Pharmaceuticals will post $-0.47 earnings per share next quarter.

A number of other analysts have also recently weighed in on AVEO. Analysts at RBC Capital (NYSE: RY) cut their price target on shares of Aveo Pharmaceuticals from $24.00 to $19.00 in a research note to investors on Friday, May 4th. They now have an “outperform” rating on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of Aveo Pharmaceuticals in a research note to investors on Monday, April 30th. They set a “buy” rating on the stock. Finally, analysts at TheStreet downgraded shares of Aveo Pharmaceuticals to a “sell” rating in a research note to investors on Monday, April 9th.

AVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics.

About the author